ReviewClinical reviews in allergy & immunology2010
Chronic granulomatous disease.
Review in Clinical reviews in allergy & immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03055247 (A Multicentric, Exploratory, Non-randomised, Non-controlled, Prospective, Open-label Phase II Study Evaluating Safety and Efficacy of IBU, G-CSF and Plerixafor as Stem Cell Mobilization Regimen in Patients Affected by X-CGD), which is not on this map. Cited by 155 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicentric, Exploratory, Non-randomised, Non-controlled, Prospective, Open-label Phase II Study Evaluating Safety and Efficacy of IBU, G-CSF and Plerixafor as Stem Cell Mobilization Regimen in Patients Affected by X-CGD
Who cites it
155 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Trends and collaborations in discoid lupus erythematosus research: a bibliometric analysis from 2010 to 2024.Frontiers in medicine · 2025Pooled it
- Pioglitazone as a novel therapeutic approach in chronic granulomatous disease.The Journal of allergy and clinical immunology · 2016Trial
- First report ofMedical mycology case reports · 2026Article
- Innate immunity: current understandings and future perspectives.Signal transduction and targeted therapy · 2026Review
- How I Treat: Chronic granulomatous disease.Journal of human immunity · 2026Review
- NLRP3 inflammasome blockade treats intestinal inflammation associated with chronic granulomatous disease.Blood · 2026Article
- Five CGD-Linked CYBB Mutations in Chinese Patients: Insights Into Predicting IFN-γ Treatment Efficacy.Journal of clinical immunology · 2025Article
- Targeting respiratory virus-induced reactive oxygen species in airways diseases.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- Tuberculosis Presenting as a Patchy Consolidation in a Young Patient With Chronic Granulomatosis Disease.Clinical case reports · 2025Article
- Review
- The pathobiology of human fungal infections.Nature reviews. Microbiology · 2024Review
- Article
- Causes of Oral Granulomatous Disorders: An Update and Narrative Review of the Literature.Head and neck pathology · 2024Review
- Integrated analysis of proteome and transcriptome revealed changes in multiple signaling pathways involved in immunity in the northern snakehead (Frontiers in cellular and infection microbiology · 2024Article
- Phage therapy to treat cystic fibrosisFrontiers in microbiology · 2024Review
- Polylactic acid-based dressing with oxygen generation and enzyme-like activity for accelerating both light-driven biofilm elimination and wound healing.Burns & trauma · 2024Article
- Unilateral cerebellar hypoplasia in a 9-year-old child with chronic granulomatous disease: A case report.Radiology case reports · 2023Article
- The pentose phosphate pathway in health and disease.Nature metabolism · 2023Review
- Nontoxic Levels of Se-Containing Compounds Increase Survival by Blocking Oxidative and Inflammatory Stresses via Signal Pathways Whereas High Levels of Se Induce Apoptosis.Molecules (Basel, Switzerland) · 2023Review
- Discovery of Homogentisic Acid as a Precursor in Trimethoprim Metabolism and Natural Product Biosynthesis.ACS chemical biology · 2023Article
95 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Chronic granulomatous disease (CGD) was first described in the 1950s and has become a paradigm for genetic neutrophil diseases. It is characterized by recurrent infections with a narrow spectrum of bacteria and fungi as well as a common set of inflammatory complications most notably including inflammatory bowel disease. Over the last half century major advances in management have profoundly altered the major clinical issues and the life expectancy of CGD. With X-linked and autosomal recessive forms, it has been an important disease for the development of bone marrow transplantation and gene therapy. Some of the recent developments in infectious syndromes, inflammatory complications, and curative approaches are discussed in this review.
Indexed as
Identifiers
19504359What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.